Show simple item record

dc.contributor.authorWang, Y
dc.contributor.authorDel Borgo, M
dc.contributor.authorLee, HW
dc.contributor.authorBaraldi, D
dc.contributor.authorHirmiz, B
dc.contributor.authorGaspari, TA
dc.contributor.authorDenton, KM
dc.contributor.authorAguilar, M-I
dc.contributor.authorSamuel, CS
dc.contributor.authorWiddop, RE
dc.date.accessioned2020-12-21T02:24:36Z
dc.date.available2020-12-21T02:24:36Z
dc.date.issued2017-08-31
dc.identifier.citationWang, Y., Del Borgo, M., Lee, H. W., Baraldi, D., Hirmiz, B., Gaspari, T. A., Denton, K. M., Aguilar, M. -I., Samuel, C. S. & Widdop, R. E. (2017). Anti-fibrotic Potential of AT(2) Receptor Agonists. FRONTIERS IN PHARMACOLOGY, 8 (AUG), https://doi.org/10.3389/fphar.2017.00564.
dc.identifier.issn1663-9812
dc.identifier.urihttp://hdl.handle.net/11343/256915
dc.description.abstractThere are a number of therapeutic targets to treat organ fibrosis that are under investigation in preclinical models. There is increasing evidence that stimulation of the angiotensin II type 2 receptor (AT2R) is a novel anti-fibrotic strategy and we have reviewed the published in vivo preclinical data relating to the effects of compound 21 (C21), which is the only nonpeptide AT2R agonist that is currently available for use in chronic preclinical studies. In particular, the differential influence of AT2R on extracellular matrix status in various preclinical fibrotic models is discussed. Collectively, these studies demonstrate that pharmacological AT2R stimulation using C21 decreases organ fibrosis, which has been most studied in the setting of cardiovascular and renal disease. In addition, AT2R-mediated anti-inflammatory effects may contribute to the beneficial AT2R-mediated anti-fibrotic effects seen in preclinical models.
dc.languageEnglish
dc.publisherFRONTIERS MEDIA SA
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleAnti-fibrotic Potential of AT(2) Receptor Agonists
dc.typeJournal Article
dc.identifier.doi10.3389/fphar.2017.00564
melbourne.affiliation.departmentBiochemistry and Molecular Biology
melbourne.source.titleFrontiers in Pharmacology
melbourne.source.volume8
melbourne.source.issueAUG
dc.rights.licenseCC BY
melbourne.elementsid1232941
melbourne.contributor.authorSamuel, Chrishan
dc.identifier.eissn1663-9812
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record